.png){kind=icon}
.png){kind=icon}
Return
November 2025 therapeutic delivery: industry update
.png){kind=icon}
PRE
AI
H
DOI：10.1080/20415990.2026.2623772.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
November 2025 saw the approval of a number of products which employ a variety of delivery technologies including Johnson and Johnson's DARZALEX FASPRO (with Haloyzyme's ENHAZE), Merck's KEYTRUDA QLEX, and Regeneron's EYLEA HD. It was also a busy month for acquisitions with Halozyme completing the acquisition of Elektrofi which gives it access to the microparticulate technology Hypercon. Halozyme also announced a collaboration with the Dutch company Merus, for the development of a subcutaneous formulation of petosemtamab. Positive clinical trial data was announced for a number of companies including EyePoint, Tiziana, Nasus, and Tonix.
Keywords:
Transdermal
ocular delivery
drug delivery
enhanced bioavailability
bioerodible
Journal
IF:
2.2
Papers:
397
Citations:
2.7K
Organization
No organization information available
Cited Papers